ADR News Bulletin 2024 April (Volume 26 Number 1)
Healthcare professional
Industry member
Therapeutic Products
29 April 2024
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Pseudoephedrine and the rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)
Analysis of adverse event reports for year 2023
AE Case in Focus 1: Test Yourself - What could have caused the blistering rash in this patient?
AE Case in Focus 2: Test Yourself - What could have caused the respiratory failure in this patient?
Click on the link below to download the issue in pdf:
ADR_News_April2024_Vol26_No1 [PDF, 2407 KB]
New drugs approved in 2023:
Healthcare professionals are encouraged to report all serious and non-serious suspected adverse drug reactions (ADRs) with the use of new drugs. Your active participation in the ADR monitoring programme will provide valuable support to the post-marketing surveillance on drug safety.
Click on the link below to download the issue in pdf:
